Literature DB >> 32753469

Phosphorylation of PLCγ1 by EphA2 Receptor Tyrosine Kinase Promotes Tumor Growth in Lung Cancer.

Wenqiang Song1,2, Laura C Kim3, Wei Han4, Yuan Hou5, Deanna N Edwards1, Shan Wang1, Timothy S Blackwell2,4,6, Feixiong Cheng5,7,8, Dana M Brantley-Sieders9,10, Jin Chen9,2,3,6,10.   

Abstract

EphA2 receptor tyrosine kinase (RTK) is often expressed at high levels in cancer and has been shown to regulate tumor growth and metastasis across multiple tumor types, including non-small cell lung cancer. A number of signaling pathways downstream of EphA2 RTK have been identified; however, mechanisms of EphA2 proximal downstream signals are less well characterized. In this study, we used a yeast-two-hybrid screen to identify phospholipase C gamma 1 (PLCγ1) as a novel EphA2 interactor. EphA2 interacts with PLCγ1 and the kinase activity of EphA2 was required for phosphorylation of PLCγ1. In human lung cancer cells, genetic or pharmacologic inhibition of EphA2 decreased phosphorylation of PLCγ1 and loss of PLCγ1 inhibited tumor cell growth in vitro. Knockout of PLCγ1 by CRISPR-mediated genome editing also impaired tumor growth in a KrasG12D-p53-Lkb1 murine lung tumor model. Collectively, these data show that the EphA2-PLCγ1 signaling axis promotes tumor growth of lung cancer and provides rationale for disruption of this signaling axis as a potential therapeutic option. IMPLICATIONS: The EphA2-PLCG1 signaling axis promotes tumor growth of non-small cell lung cancer and can potentially be targeted as a therapeutic option. ©2020 American Association for Cancer Research.

Entities:  

Year:  2020        PMID: 32753469      PMCID: PMC7641970          DOI: 10.1158/1541-7786.MCR-20-0075

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  41 in total

Review 1.  Phospholipase C-gamma as a signal-transducing element.

Authors:  G Carpenter; Q s Ji
Journal:  Exp Cell Res       Date:  1999-11-25       Impact factor: 3.905

Review 2.  Multiple roles of phosphoinositide-specific phospholipase C isozymes.

Authors:  Pann-Ghill Suh; Jae-Il Park; Lucia Manzoli; Lucio Cocco; Joanna C Peak; Matilda Katan; Kiyoko Fukami; Tohru Kataoka; Sanguk Yun; Sung Ho Ryu
Journal:  BMB Rep       Date:  2008-06-30       Impact factor: 4.778

Review 3.  Dysfunction of phospholipase Cγ in immune disorders and cancer.

Authors:  Hans Koss; Tom D Bunney; Sam Behjati; Matilda Katan
Journal:  Trends Biochem Sci       Date:  2014-10-30       Impact factor: 13.807

4.  Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation.

Authors:  Ta-Ming Liu; Jennifer A Woyach; Yiming Zhong; Arletta Lozanski; Gerard Lozanski; Shuai Dong; Ethan Strattan; Amy Lehman; Xiaoli Zhang; Jeffrey A Jones; Joseph Flynn; Leslie A Andritsos; Kami Maddocks; Samantha M Jaglowski; Kristie A Blum; John C Byrd; Jason A Dubovsky; Amy J Johnson
Journal:  Blood       Date:  2015-05-13       Impact factor: 22.113

5.  FGFR1 Induces Glioblastoma Radioresistance through the PLCγ/Hif1α Pathway.

Authors:  Valérie Gouazé-Andersson; Caroline Delmas; Marion Taurand; Judith Martinez-Gala; Solène Evrard; Sandrine Mazoyer; Christine Toulas; Elizabeth Cohen-Jonathan-Moyal
Journal:  Cancer Res       Date:  2016-02-19       Impact factor: 12.701

6.  Ligand-independent EPHA2 signaling drives the adoption of a targeted therapy-mediated metastatic melanoma phenotype.

Authors:  Kim H T Paraiso; Meghna Das Thakur; Bin Fang; John M Koomen; Inna V Fedorenko; Jobin K John; Hensin Tsao; Keith T Flaherty; Vernon K Sondak; Jane L Messina; Elena B Pasquale; Alejandro Villagra; Uma N Rao; John M Kirkwood; Friedegund Meier; Sarah Sloot; Geoffrey T Gibney; Darrin Stuart; Hussein Tawbi; Keiran S M Smalley
Journal:  Cancer Discov       Date:  2014-12-26       Impact factor: 39.397

Review 7.  The physiological roles of primary phospholipase C.

Authors:  Yong Ryoul Yang; Matilde Y Follo; Lucio Cocco; Pann-Ghill Suh
Journal:  Adv Biol Regul       Date:  2013-08-27

8.  EphA2 in the early pathogenesis and progression of non-small cell lung cancer.

Authors:  Jennifer M Brannan; Banibrata Sen; Babita Saigal; Ludmila Prudkin; Carmen Behrens; Luisa Solis; Wenli Dong; B Nebiyou Bekele; Ignacio Wistuba; Faye M Johnson
Journal:  Cancer Prev Res (Phila)       Date:  2009-11-24

9.  Host deficiency in Vav2/3 guanine nucleotide exchange factors impairs tumor growth, survival, and angiogenesis in vivo.

Authors:  Dana M Brantley-Sieders; Guanglei Zhuang; David Vaught; Tanner Freeman; Yoonha Hwang; Donna Hicks; Jin Chen
Journal:  Mol Cancer Res       Date:  2009-05-12       Impact factor: 5.852

10.  The Ephrin-A1/EPHA2 Signaling Axis Regulates Glutamine Metabolism in HER2-Positive Breast Cancer.

Authors:  Victoria M Youngblood; Laura C Kim; Deanna N Edwards; Yoonha Hwang; Pranav R Santapuram; Steven M Stirdivant; Pengcheng Lu; Fei Ye; Dana M Brantley-Sieders; Jin Chen
Journal:  Cancer Res       Date:  2016-02-01       Impact factor: 12.701

View more
  2 in total

1.  Identification of the Pyroptosis-Related Prognosis Gene Signature and Immune Infiltration in Hepatocellular Carcinoma.

Authors:  Heng Yu; Xue Bai; Wangyang Zheng
Journal:  Dis Markers       Date:  2022-04-30       Impact factor: 3.464

Review 2.  Oncogenic functions and therapeutic targeting of EphA2 in cancer.

Authors:  Kalin Wilson; Eileen Shiuan; Dana M Brantley-Sieders
Journal:  Oncogene       Date:  2021-03-08       Impact factor: 9.867

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.